Gutierrez-Peña Mauricio, Zuñiga-Macias Leslie, Marin-Garcia Ricardo, Ovalle-Robles Itzel, García-Díaz Andrea L, Macías-Guzmán Mariana J, Delgado-Bentites Angel, Macías-Diaz Dulce Maria, Prado-Aguilar Carlos Alberto, Vega de la Rosa Alejandro, Delgadillo-Castañeda Rodolfo, Chew-Won Alfredo, Reyes-Acevedo Rafael, Reyes-Campos Dulce Maria, Martínez-Guevara Marco Antonio, Mendoza-Enciso Emanuel A, Nava-Becerra Bernardo, Piza-Jiménez Miguel Angel, Arreola Guerra José Manuel
Aguascalientes Institute of Health Services, Aguascalientes, Mexico.
Department of Internal Medicine, Hospital Centenario Miguel Hidalgo, Aguascalientes, Mexico.
Clin Kidney J. 2021 Jan 15;14(4):1197-1206. doi: 10.1093/ckj/sfaa229. eCollection 2021 Apr.
Chronic kidney disease (CKD) is one of the pathologies with the greatest impact on the public health system. Over the last few decades, the relevance of CKD in Mexico has increased, with associated overwhelming costs for care of renal disease. There are no reliable CKD statistics in Mexico.
In June 2018, the government of Aguascalientes called on all Health Institutions to create a state registry of treated end-stage renal disease (ESRD). In the same system, a renal biopsy result registry included all the native kidney biopsies obtained in the state of Aguascalientes since 2012. We herein describe the prevalence, incidence and characteristics of the patients included in the CKD and renal biopsy registry in the state of Aguascalientes.
As of April 2020, the state has documented 2827 patients on renal replacement therapy (RRT), 1877 on dialysis and 950 that have been transplanted. The prevalence of patients on dialysis is 1326 per million population (p.m.p.), and if transplanted individuals are included, it is 1997 p.m.p. The incidence of treated ESRD in 2019 was 336 p.m.p. ( = 474) in individuals with an average age of 45.6 years (standard deviation ±18), and in a higher proportion of men (61%). There is a bimodal distribution of the age at which RRT was initiated. The first and the most significant peaks are between the ages of 20 and 40 years and are usually the result of CKD of unknown cause (73%). The second peak is between 50 and 70 years of age, and CKD is usually the result of diabetes mellitus and systemic arterial hypertension (59.6%). Since January 2012, 423 biopsies have been recorded. The patient's ages were between 20 and 30 years ( = 112), and the most frequent diagnosis was focal segmental glomerulosclerosis (FSGS) (54%).
The prevalence of treated ESRD in the state of Aguascalientes is high. The disease mostly afflicts young people between 20 and 40 years of age, and there is a clear male predominance. In this age group, the main clinical diagnosis is CKD of unknown origin, and the most frequent biopsy diagnosis was FSGS.
慢性肾脏病（CKD）是对公共卫生系统影响最大的病症之一。在过去几十年中，CKD在墨西哥的相关性有所增加，伴随而来的是肾病护理的巨大成本。墨西哥没有可靠的CKD统计数据。
2018年6月，阿瓜斯卡连特斯州政府呼吁所有卫生机构创建一个已治疗终末期肾病（ESRD）的州登记册。在同一系统中，肾脏活检结果登记册包括自2012年以来在阿瓜斯卡连特斯州获得的所有自体肾活检。我们在此描述阿瓜斯卡连特斯州CKD和肾脏活检登记册中患者的患病率、发病率和特征。
截至2020年4月，该州已记录2827例接受肾脏替代治疗（RRT）的患者，1877例接受透析，950例接受移植。透析患者的患病率为每百万人口1326例（p.m.p.），如果包括移植个体，则为1997 p.m.p.。2019年接受治疗的ESRD发病率为每百万人口336例（n = 474），患者平均年龄为45.6岁（标准差±18），男性比例较高（61%）。开始RRT的年龄呈双峰分布。第一个也是最显著的峰值在20至40岁之间，通常是由不明原因的CKD导致的（73%）。第二个峰值在50至70岁之间，CKD通常是由糖尿病和系统性动脉高血压导致的（59.6%）。自2012年1月以来，已记录423例活检。患者年龄在20至30岁之间（n = 112），最常见的诊断是局灶节段性肾小球硬化（FSGS）（54%）。
阿瓜斯卡连特斯州接受治疗的ESRD患病率很高。该疾病主要影响20至40岁的年轻人，男性明显占主导地位。在这个年龄组中，主要的临床诊断是不明原因的CKD，最常见的活检诊断是FSGS。
Zotero 插件
